CDC25 (Debio 0931) is a key enzyme involved in the regulation of cell cycles and is expected to have many applications in treating common forms of cancer.
As per the agreement, Debiopharm will be exclusively responsible for the development of Debio 0931. Ipsen will have the option to re-acquire development and commercialisation rights post completion of Phase II clinical trials.
Ipsen will also receive an upfront payment and be eligible for milestone payments and royalties.
Ipsen chairman and chief executive officer Jean-Luc Belingard said that he was delighted that Ipsen’s CDC-25 inhibitor will progress toward clinical development.
“Debiopharm is our long-standing partner with whom we have had a very fruitful partnership in other areas of oncology for more than 20 years,” Belingard said.